CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
将 CAR-T 细胞免疫疗法的交响乐与生物材料的优雅和谐统一
英文原题：Harmonizing the symphony of chimeric antigen receptor T cell immunotherapy with the elegance of biomaterials.
查看英文原题
Harmonizing the symphony of chimeric antigen receptor T cell immunotherapy with the elegance of biomaterials.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞免疫疗法已成为癌症研究的热点领域，在难治性和复发性血液系统恶性肿瘤中展现出革命性的疗效。然而，CAR-T 疗法仍面临严峻挑战，包括复杂冗长的制备流程、靶向递送效果欠佳、对实体瘤的治疗效果有限以及难以进行实时体内监测。为克服这些局限性，多种多功能生物材料已被应用于上述方面，并显著提升了CAR-T 疗法的效果。本综述主要总结了生物材料在促进CAR-T 疗法制造、增强靶向递送与肿瘤浸润以及实现显著的体内追踪方面的最新研究进展，为临床治疗提供新的见解和启发。
展开英文摘要原文
Chimeric antigen receptor T cell (CAR-T) immunotherapy has become a heated field of cancer research, demonstrating revolutionary efficacy in refractory and relapsed hematologic malignancies.
However, CAR-T therapy has still encountered tough challenges, including complicated and lengthy manufacturing procedures, mediocre targeted delivery, limited therapeutic effect against solid tumors and difficulties in real-time in vivo monitoring. To overcome these limitations, various versatile biomaterials have been used in the above aspects and have improved CAR-T therapy impressively.
This review mainly summarizes the latest research progress of biomaterials promoting CAR-T therapy in manufacturing, enhancing targeted delivery and tumor infiltration, and dramatic in vivo tracking to provide new insights and inspiration for clinical treatment.
论文信息
- 作者
- Chen Z、Hu Y、Mei H
- 第一作者单位
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, Hubei, China; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China.China
- 通讯作者单位
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, Hubei, China; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China. Electronic address: hmei@hust.edu.cn.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Trends in biotechnology2025 Feb
- 原文标识
- PubMed 39181760 · DOI 10.1016/j.tibtech.2024.07.017